Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : U.S. to buy 1.4 mln additional doses of Regeneron's COVID-19 therapy

09/14/2021 | 05:47pm EDT

Sept 14 (Reuters) - Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government will buy 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV.

The cocktail, a combination of two antibodies casirivimab and imdevimab, was authorized in November for emergency use by the U.S. Food and Drug Administration.

The new agreement brings the total purchased by the U.S. government to nearly 3 million doses. (Reporting by Dania Nadeem in Bengaluru; Editing by Anil D'Silva)


ę Reuters 2021
All news about REGENERON PHARMACEUTICALS
10:08aREGENERON PHARMACEUTICALS : New dupixent (dupilumab) data in patients as young as six year..
AQ
09:42aWALL STREET STOCK EXCHANGE : Fed verdict is imminent
06:34aANALYST RECOMMENDATIONS : Blackstone, Burberry, FedEx, Hershey, Micron Technology...
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/21REGENERON PHARMACEUTICALS : BMO Capital Adjusts Regeneron Pharmaceuticals' Price Target to..
MT
09/21REGENERON PHARMACEUTICALS : New Dupixent« (dupilumab) Data in Patients as Young as Six Yea..
PR
09/20REGENERON PHARMACEUTICALS : Esmo late-breaking data show libtayo (cemiplimab) and chemothe..
AQ
09/20SANOFI : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line t..
AQ
09/20Biogen, Samsung Bioepis Get FDA OK for Lucentis Biosimilar
DJ
09/20SANOFI : Regeneron, Sanofi Say Lung Cancer Drug Libtayo Improves Overall Patient Survival ..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 13 864 M - -
Net income 2021 6 822 M - -
Net cash 2021 6 794 M - -
P/E ratio 2021 10,3x
Yield 2021 -
Capitalization 67 262 M 67 262 M -
EV / Sales 2021 4,36x
EV / Sales 2022 4,75x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 646,95 $
Average target price 681,41 $
Spread / Average Target 5,33%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS33.91%67 262
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.36.63%69 407
VERTEX PHARMACEUTICALS-21.38%48 202
BEIGENE, LTD.50.36%36 146